Hyperuricemia
Conditions
Interventions
placebo group:Placebo
Probiotic treatment group:Probiotic treatment
Security Testing Team:Probiotic treatment
Sponsors
Shandong Provincial Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Non same day, twice fasting blood uric acid>420 µ mol/L; 2.Age between >= 18 years old and = 3 months; 4.Not using uric acid lowering drugs within 8 weeks prior to screening; 5.BMI >= 18.5kg/m^2 and <= 35kg/m^2; 6.If hypertension, type 2 diabetes and hyperlipidemia are combined, the medication should be stable 8 weeks before enrollment, and the condition should be controlled stably. During the study period, there is no need to adjust the original treatment drugs. 7.Triglycerides <= 500 mg/dL (5.65 mmol/L); Total cholesterol (TC) <= 250mg/dl (6.45mmol/L). 8.Voluntarily sign an informed consent form before screening and agree to be randomly assigned to any experimental group.
Exclusion criteria
Exclusion criteria: 1.Known allergy constitution or previous allergy to probiotic preparations; 2.Acute gout attack period; 3.Participated in clinical trials of other drugs within 3 months prior to the screening period; 4.Individuals who have taken probiotics or antibiotics within the past 4 weeks prior to screening; 5.Those with poor blood pressure control, i.e. systolic blood pressure (SBP)>160mmHg and/or diastolic blood pressure (DBP)>100mmHg; 6.Triglycerides (TG)>500 mg/dL (5.65 mmol/L) and/or total cholesterol (TC)>250 mg/dL (6.45 mmol/L). 7.Transient cerebral ischemia, cerebrovascular accident, unstable angina, acute pancreatitis, diabetes acute complications or serious diabetes chronic complications occurred within 6 months before screening; History of myocardial infarction, coronary angioplasty or coronary artery bypass surgery in the past; Cardiac dysfunction (NYHA classification III/IV); 8.Having liver diseases such as cirrhosis, active hepatitis, or ALT and AST levels exceeding 2.5 times the upper limit of normal; Severe kidney disease, eGFR< 45ml/min/1.73m^2; 9.Any conditions or comorbidities that researchers determine may interfere with the test results, such as cardiovascular, respiratory, gastrointestinal, pancreatic diseases, liver, kidney, nervous system, psychiatric, hematological, immune system diseases, or other malignant tumors; 10.Screening for drugs that may have a significant impact on uric acid metabolism, such as steroid hormones, immunosuppressants, etc., within the first 4 weeks or expected to be used; 11.Patients with other mental illnesses who are unable or unwilling to cooperate; Or other situations that the researcher deems unsuitable for research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood uric acid concentration; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood inflammatory factor concentration;gut flor; | — |
Countries
China
Contacts
Public ContactXinfeng Bai
Shandong Provincial Third Hospital
Outcome results
None listed